Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa ...

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa ...

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Labcorp (LH) announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the ...

Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on ...

Researchers have developed a blood test based on a protein biomarker for tau tangles that can help diagnose Alzheimer’s ...